Repligen Corp. (NASDAQ:RGEN) is up 5.38% intraday at $145.84 on above-average volume as Merck KGaA's $11.3 billion acquisition of Bio-Techne at a 36% premium directly confirms that large life-science conglomerates value high-quality bioprocess tools platforms at substantial strategic premiums.
Key Highlights
• Repligen is up 5.38% intraday at $145.84, holding near session highs on above-average volume, a technically constructive sign of sustained institutional buying.
• Merck KGaA's $11.3 billion acquisition of Bio-Techne at a 36% premium is the most directly verifiable M&A read-through for Repligen, whose filtration and chromatography products serve the same biologics manufacturing customers.
• Repligen has been significantly de-rated over the past two years from post-COVID bioprocess inventory digestion headwinds; the M&A read-through re-rating is credible and supported by the strategic adjacency.
• No Repligen-specific announcement was released today; full-year guidance and order recovery trends are the next fundamental catalysts.
Cleanest M&A Read-Through in Today's Session
Repligen Corp. (NASDAQ:RGEN), a Waltham, Massachusetts-based life science tools and bioprocess company providing filtration, chromatography, and analytics products used in the manufacture of biologics including monoclonal antibodies, gene therapies, and mRNA therapeutics, is up 5.38% intraday at $145.84. This is one of the cleanest and most directly verifiable M&A read-through stories in today's session.
Merck KGaA's $11.3 billion acquisition of Bio-Techne at a 36% premium confirmed that large life-science conglomerates are actively acquiring high-quality bioprocess tools platforms. Repligen's proprietary filtration and chromatography product lines sit in direct strategic adjacency to Bio-Techne's protein and antibody catalogues: both companies serve the same biologics manufacturing customers and benefit from the same long-term bioproduction growth trend. Intraday price action is strong and sustained, holding near session highs on above-average volume, a technically constructive signal of institutional buying.
Post-COVID De-Rating and the Recovery Case
Repligen has been significantly de-rated over the past two years due to post-COVID bioprocess inventory digestion headwinds. During the pandemic, pharmaceutical companies built substantial inventory buffers for bioprocess consumables and equipment, which subsequently reduced ordering rates as those buffers were worked down. This inventory digestion cycle suppressed Repligen's revenue growth and compressed its multiple from peak pandemic-era levels.
The Bio-Techne acquisition re-rating is particularly credible for Repligen because the strategic rationale is identical to what drove the Bio-Techne deal: acquiring proprietary, high-barrier-to-entry tools platforms that serve the biologics manufacturing supply chain. As inventory digestion in the bioprocess sector normalises and order rates recover, Repligen's organic revenue trajectory would improve simultaneously with any M&A premium the market assigns to the strategic asset value.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...